Vir Biotechnology is a US healthcare company focusing on clinical-stage immunology. Founded in 2016 with headquarters in San Francisco, it’s dedicated to creating a world without infectious disease using its cutting-edge technologies. The company’s process is to first identify limitations of a patient’s immune system for combatting a particular pathogen, and when it has detected the vulnerabilities of the pathogen, it can then apply technologies using its antibody platform that will lead to effective treatment. Diseases that Vir has treated include Hepatitis B, Covid-19, influenza and HIV/AIDS. Vir Biotechnology stock is listed on the Nasdaq exchange. Start spread betting or trading CFDs on our Vir Biotechnology share price.